A review of retroperitoneal liposarcoma genomics.
Tyler, Robert Taniere, Philippe Almond, Max Ford, Samuel Desai, Anant Beggs, Andrew
Tyler, Robert
Taniere, Philippe
Almond, Max
Ford, Samuel
Desai, Anant
Beggs, Andrew
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2020-03-28
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their extremity counterparts. Within their subtypes - well differentiated (WDL), dedifferentiated (DDL), myxoid (MLS) and pleomorphic (PLS) - they exhibit a diverse genomic landscape. With recent advances in next generation sequencing, the number of studies exploring this have greatly increased. The recent literature has deepened our understanding of the hallmark MDM2/CDK4 amplification in WDL/DDL and addressed concerns about toxicity and resistance when targeting this. The FUS-DDIT3 fusion gene remains the primary focus of interest in MLS with additional potential targets described. Whole genome sequencing has driven identification of novel genes and pathways implicated in WDL/DDL outside of the classic 12q13-15 amplicon. Due to their rarity; anatomical location and histologic subtype are infrequently mentioned when reporting the results of these studies. Reports can include non-adipogenic or extremity tumours, making it difficult to draw specific retroperitoneal conclusions. This narrative review aims to provide a summary of retroperitoneal liposarcoma genomics and the implications for therapeutic targeting.
Citation
Tyler R, Wanigasooriya K, Taniere P, Almond M, Ford S, Desai A, Beggs A. A review of retroperitoneal liposarcoma genomics. Cancer Treat Rev. 2020 Jun;86:102013. doi: 10.1016/j.ctrv.2020.102013. Epub 2020 Mar 28
Type
Article
Other
Other